Skip to main content
. 2020 Mar 25;111(5):1685–1691. doi: 10.1111/cas.14368

TABLE 2.

Treatment

Type of treatment No. of patients (%)
1st line treatment
Concurrent chemoradiotherapy 1598 (13.0)
Sequential chemoradiotherapy 200 (1.6)
Thoracic radiotherapy 782 (6.3)
Chemotherapy 6736 (54.7)
Palliative care 2993 (24.3)
Others 11 (0.1)
Total 12 320 (100.0)
Chief treatment through all lines
Concurrent chemoradiotherapy 1689 (13.7)
Sequential chemoradiotherapy 221 (1.8)
Thoracic radiotherapy 662 (5.4)
Chemotherapy 7790 (63.2)
NSCLC use of EGFR‐TKIs yes 2053 (26.4) a
NSCLC use of EGFR‐TKIs no 4105 (52.6) a
SCLC use of EGFR‐TKIs no 1613 (20.7) a
SCLC use of EGFR‐TKIs yes 6
Histology unknown 13
Palliative care alone 1952 (15.8)
Others 6 (0.1)
Total 12 320 (100.0)

Abbreviations: EGFR‐TKI, epidermal growth factor receptor‐tyrosine kinase inhibitor; NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer.

a

The percentage among patients treated with chemotherapy alone.